# NEW DRUG APPROVAL UPDATE! Understanding Zaynich

**URL:** <https://www.medboundhub.com/t/new-drug-approval-update-understanding-zaynich/20567>\
**Category:** General\
**Created:** [June 25, 2026, 3:57am UTC](https://www.medboundhub.com/t/new-drug-approval-update-understanding-zaynich/20567 "2026-06-25T03:57:43Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Kavishri17](https://yyz1.discourse-cdn.com/flex033/user_avatar/www.medboundhub.com/kavishri17/32/3093_2.png) [@Kavishri17](https://www.medboundhub.com/u/Kavishri17)\
**Post date:** [June 25, 2026, 3:57am UTC](https://www.medboundhub.com/t/new-drug-approval-update-understanding-zaynich/20567/1 "2026-06-25T03:57:43Z")

</div>

**Cefepime–Zidebactam** (brand name **ZAYNICH** ) developed by Wockhardt is a relatively new antibiotic combination .  
**In India**  
It’s approved by the **Central Drugs Standard Control Organisation (CDSCO)** / DCGI on **27 May 2026** , \* for the treatment of **complicated urinary tract infections (cUTI)**, including **pyelonephritis** , and cases with concurrent Gram-negative bacteremia in adults.

It is Approved by the **U.S. Food and Drug Administration (FDA)** on **30 May 2026** under the brand name **ZAYNICH®** , for adults with complicated urinary tract infections caused by susceptible Gram-negative organisms.

The unique thing about its approval is-

- It is the **first new chemical entity (NCE) antibiotic fully discovered and developed by an Indian pharmaceutical company to receive FDA approval**.
- It introduces a **first-in-class dual PBP-targeting mechanism** (PBP2 and PBP3), offering activity against many multidrug-resistant and extensively drug-resistant Gram-negative pathogens.  
Mechanism of action:
- **Cefepime** : A fourth-generation cephalosporin antibiotic that Binds primarily to **PBP3** (Penicillin- binding protein) inhibits bacterial cell wall synthesis.
- **Zidebactam** : A β-lactam enhancer with intrinsic antibacterial activity that binds strongly to Penicillin-Binding Protein 2 (PBP2).  
Antimicrobial Spectrum of the drug  
Active against many resistant Gram-negative pathogens, including:  
• Escherichia coli  
• Klebsiella pneumoniae  
• Pseudomonas aeruginosa  
• Acinetobacter baumannii  
• Enterobacter species

**Clinical uses include-**

- Hospital-acquired pneumonia (HAP)
- Ventilator-associated pneumonia (VAP)
- Complicated urinary tract infections (cUTI)
- Complicated intra-abdominal infections
- Bloodstream infections caused by susceptible MDR Gram-negative bacteria

MBH/DB